New Jersey Trim Clinic

Semaglutide Side Effects: What New Jersey Patients Should Know

Published by New Jersey Trim Clinic · Updated 2025-03-20

Understanding Semaglutide Side Effects

Before starting any medication, understanding the potential side effects is an important part of making an informed decision. Semaglutide, like all prescription medications, carries potential risks that should be discussed with your medical provider. This article provides an overview of what New Jersey patients should know.

Common Side Effects

The most frequently reported side effects of semaglutide are gastrointestinal in nature. These include nausea, which is the most common side effect and is typically most pronounced during the first few weeks of treatment and during dose increases. Decreased appetite is part of how the medication works but can feel unfamiliar at first. Diarrhea or constipation may occur and usually improves as the body adjusts. Abdominal discomfort or bloating can occur, particularly after large meals. Vomiting may occur in some patients, especially during dose escalation.

These side effects are generally mild to moderate and tend to diminish over time as the body adjusts to the medication. The gradual dose-escalation protocol used in semaglutide treatment is specifically designed to minimize these effects.

Managing Common Side Effects

Several strategies can help manage common side effects. Eating smaller, more frequent meals rather than large portions can reduce nausea and bloating. Staying hydrated is important, particularly if experiencing diarrhea. Avoiding high-fat and greasy foods during the adjustment period may reduce gastrointestinal discomfort. Your provider may slow the dose escalation if side effects are particularly bothersome.

Less Common but Important Side Effects

Less common side effects that warrant attention include headache, fatigue, and dizziness. Injection site reactions such as redness or mild irritation are possible. Changes in taste perception have been reported by some patients. Gallbladder-related issues including gallstones can occur, particularly with rapid weight loss.

Serious Side Effects and Contraindications

Semaglutide carries warnings about potential serious risks. Pancreatitis is a rare but serious condition. Symptoms include severe abdominal pain that does not go away. If you experience this, contact your provider immediately. Thyroid tumors have been observed in animal studies with GLP-1 medications. Semaglutide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Kidney problems may be exacerbated by dehydration related to gastrointestinal side effects.

The Role of Medical Supervision

This is precisely why physician supervision matters. A qualified provider monitors you throughout treatment, watches for concerning symptoms, adjusts doses as needed, and can discontinue treatment if side effects become problematic. Self-medicating with semaglutide — or obtaining it without proper medical oversight — removes this safety net.

During your regular telehealth check-ins with New Jersey Trim Clinic, your provider will specifically ask about side effects and assess whether your treatment plan needs adjustment.

Making an Informed Decision

Understanding side effects is not meant to discourage you from considering semaglutide. For many patients, the benefits significantly outweigh the risks. But this decision should be made with full information, in consultation with a licensed medical provider who has reviewed your complete health profile.

New Jersey Trim Clinic provides thorough medical evaluations and ongoing physician oversight for all patients. We believe informed patients make better decisions about their health. Schedule your free consultation to discuss whether semaglutide is appropriate for your situation.

MEDICAL SOURCES & FURTHER READING

Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.

  • NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity

    Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.

  • Mayo Clinic — Prescription weight-loss drugs

    Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.

  • Cleveland Clinic — GLP-1 Agonists

    Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.

    Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.

    Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.

  • FDA — Wegovy (semaglutide) prescribing information

    Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.

    Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.

  • The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

    Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.

    Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.

  • FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.

    Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.

RESEARCH & REFERENCES

General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.

Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.

Browse more New Jersey Trim Clinic patient education.